RE:RE:RE:Thoughts on why our phase II targeted a 40% efficacy....
So what that means is that MCNA clearly doesn't meet the minimum requirements set forth by the FDA for a successful single arm trial. It seems to me that this should be very concerning for anyone expecting an FDA approval in February. Wouldn't the FDA be going against its own guidance by approving? Are there any examples of the FDA doing this in the past?